M existing therapies for the rheumatic diseases collagen in joint tissues in health and disease. In situ hybridization techniques have been used to measure relieve the pain and swelling associated with the disease, but have little effect on the underlying destruction collagenase gene expression in synovial and cartilage tissue from diseased joints [7] [8] [9] [10] . Other studies have of tissue and the corresponding loss of function. Although Voltaire cynically stated that 'The art of measured MMP protein in these tissues by immunohistochemistry [11] . MMPs have been extracted from medicine is the ability to keep the patient entertained whilst the disease runs its inevitable course', rheumatodiseased tissues and assayed by activity or using immunoassays [12, 13] . Finally, the levels of MMP logists have long expressed the need for drugs that prevent joint damage. The second-line agents currently protein have been measured in synovial fluids and serum samples from patients [14, 15] . If these proin use, so-called disease-modifying drugs, have mainly been adapted for the rheumatic diseases from other teinases are involved in tissue destruction, then they could represent a new therapeutic target that would specialities and the mechanism and/or target of action is not always clear. Although some of these drugs do allow the prevention of tissue destruction. Any attempt to prevent tissue damage by targeting the MMPs could slow the progression of joint destruction [1] , recent developments have increased our understanding of the follow a number of different strategies. These include blocking the production of MMPs, inhibiting the different disease mechanisms involved and led to the identification of new targets. There is a clear need for enzymes responsible for activation of proMMPs, increasing the amount of TIMPs available, thus new therapeutic approaches that block precise steps in the disease processes and some of these are in the early blocking MMP activity, or directly inhibiting the activated enzymes (reviewed in [16 ] , [17] ). stages of development [1] .
The destruction of connective tissues such as cartilThe direct inhibition of MMPs as a therapeutic approach has been followed for a number of years. age and bone is the final stage of many diseases of the joint. Both the major proteins of cartilage, proteo-
The antibiotic tetracycline shows some activity as an inhibitor of collagenase. Direct inhibitory activity is glycan and collagen, are degraded. In normal human cartilage, proteoglycan pulls water into the tissue and noted primarily against MMP-8 and the collagenases also autodegrade in the presence of this class of comswells against a type II collagen fibrillar network. This structure gives cartilage its tensile strength whilst pound. Greater activity is seen with some modified tetracyclines [18, 19] and collagenolysis is inhibited in allowing it to resist compression. Whilst proteoglycan can be readily replaced by the chondrocytes in cartilvivo and in vitro [20] . Recent data from animal models suggest that the levels of collagenase and gelatinase age, the loss of the collagen network leads to irreversible damage. This makes collagen breakdown a key are reduced, but with no overall reduction in bone and joint damage [21] . Patient studies have resulted in therapeutic target [2] . Of the four main classes of proteinases that can degrade proteins, the serine and contradictory findings, although they do suggest that, in combination with NSAIDs, these compounds prometalloproteinases act extracellularly at neutral pH and could therefore be responsible for the breakdown tect joints, and further studies are in progress with newer derivatives of these compounds [18, 22] . The of the extracellular matrix [3] .
Collagen can be specifically cleaved by the collaobvious and clear advantage of this class of compounds is that they are already in clinical use and could give genases, members of a family of zinc-containing enzymes called the matrix metalloproteinases (MMPs).
useful data on the inhibition of MMPs as a therapeutic strategy. The disadvantages are that they have a relaMMPs can degrade proteins of the extracellular matrix and often require specific stimuli to upregulate their tively low potency and, as they are licensed for a considerable period of time, the cost of extensive and production [4] . The pro-inflammatory cytokines upregulate many MMPs which are synthesized as prolengthy trials will be difficult to find. Other more targeted approaches have been followed. enzymes and require activation before substrate can be degraded [5] . The active forms of each enzyme can MMPs are related to the metallopeptidase angiotensin converting enzyme (ACE) and synthetic inhibitors be inhibited by tissue inhibitors of metalloproteinases ( TIMPs), inhibitors that specifically block the action have been made that block the action of ACE. These inhibitors have a chelating group (hydroxamate) of this family of proteinases [6 ] . If the amount of active MMPs exceeds the locally available TIMPs, attached to a peptide mimic of the sequence of amino acids cleaved by the enzyme in angiotensin I. When then connective tissue turnover is the result.
There are three human collagenases (MMP-1, these inhibitors were screened against MMPs, it was discovered that a stereoisomer, inactive against ACE, MMP-8 and MMP-13) and there is good evidence that these enzymes are closely involved in the turnover of gave significant inhibition. This early lead allowed the synthesis of inhibitors that mimicked the cleavage site triple helix. Some workers have suggested that as in collagen attached to a chelating group that had MMP-13 cleaves Type II collagen most efficiently of activity in the micromolar range [23] [24] [25] . Other all the collagenases, then this enzyme is responsible approaches to developing specific inhibitors have for normal turnover whilst MMP-1 might be especiattempted to copy the peptide sequences in the propepally damaging in disease. Others suggest that MMP-13 tide region of MMPs or to mimic sites cleaved during is responsible for the majority of damage caused in the activation of MMPs or in certain inhibitors such the arthritides. There is no doubt that there are as a 2 -macroglobulin. differences in specificity, location and control mechanThese early inhibitors, although relatively potent isms with these two collagenases. Chondrocytes are with activities in the nanomolar range, were often not also able to produce MMP-8 in addition to MMP-1 active in vivo after oral dosing as they were metaband MMP-13, and recent work has shown that this olized. Considerable effort was made to overcome these collagenase is also found in osteoarthritic cartilage problems and a number of inhibitors are now available tissue [34] in addition to being stored in neutrophils. that are biologically active and potent [26] [27] [28] . The
Mitchell et al. [10] showed that out of six design of orally active inhibitors is still largely empirosteoarthritis (OA) cartilages, five had MMP-1 preical; removal of peptide bonds prevents proteolysis and sent, four had MMP-13 and some samples had one limiting the number of hydrogen bond donors increases collagenase with no trace of the other. It is likely that absorption [29] , presumably by lowering the energy all three collagenases are important, but to differing required to pass from the aqueous to the lipid environdegrees in different diseases. ment of the gut wall membrane. Effective inhibitors As synthetic MMP inhibitors block the metastatic will need to remain biologically active and penetrate traffic of tumour cells, angiogenesis, and tumour the cartilage matrix. invasion in animal models, then the early clinical Further improvement of MMP synthetic inhibitors trials were conducted in patients with various cancers was possible after the crystal structures of the [35, 36 ] . Whilst proving to be partially effective in active site cleft of collagenase-1, collagenase-2 and blocking the progression of different tumours, treatstromelysin-1 became available. Potent inhibitors with ment was associated with joint pain, particularly in specificity for individual enzymes are now possible.
the shoulder and the hand, in a time-and doseFor example, a series of inhibitors were made for dependent way in about a third of patients on the MMP-2 that were shown to be highly specific for this highest dose. These symptoms would disappear if enzyme [30] and some inhibitors have been shown to treatment was stopped for a period of time. One be specific for MMP-13 [31] .
explanation for the occurrence of these side-effects is A number of issues remain controversial. It is not that the MMP inhibitors are blocking the normal known what type of MMP inhibitor should be tested turnover of the connective tissues surrounding the first. Broad-spectrum inhibitors tend to inhibit all joint. These symptoms can be reproduced in animal MMPs (including any not yet discovered ) plus enzymes models (both rat and marmoset) and new compounds that belong to closely related classes. Thus, in early under development can now be screened in rodent trials, in addition to sparing joint tissue destruction, models to eliminate compounds with this side-effect these synthetic inhibitors also reduced joint pain and profile. Whether it is sufficient just to screen these swelling. This effect was mediated by inhibition of the compounds in rodent models is debatable since the tumour necrosis factor alpha ( TNF-a) convertase MMP profile of humans and rodents is obviously which belongs to a different but closely related family different in relation to the collagenases. [32, 33]. However, broad-spectrum inhibitors may lead Currently, a number of compounds are being to undesirable side-effects (see below). Alternatively, developed for the treatment of the rheumatic diseases. highly specific inhibitors could be used if the destrucThe initial trials of MMP inhibitors will take place in tion of tissue in a particular disease was caused by an rheumatoid arthritis ( RA) as here the destruction of individual MMP.
tissue is more rapid than in OA. Patients should be It is not yet known which will be the most treated in the early stages of disease rather than in appropriate collagenase to target specifically. MMP-1 established disease where most tissue destruction has is widely distributed, MMP-13 is found in chondroalready occurred. Different mechanisms are likely to cytes and osteoblasts. MMP-8 is stored in neutrophils.
be responsible for the modulation of these enzymes in MMP-1-TIMP-1 complexes can be found in rheumat-RA compared to OA. The destruction of collagen in oid synovial fluid, indicating that MMP-1 is activated OA is more focal and also the metabolic rate for the within the rheumatoid joint [15] . Convincing evidence tissue as a whole is increased. This makes it more for a role of MMP-13 in cartilage degradation in vitro difficult to treat by specifically blocking degradation was presented where synthetic inhibitors targeted to as there are also focal areas of excess synthesis with MMP-13 were effective at concentrations where the formation of osteophytes. If direct evidence of the MMP-1 was not inhibited [29] . MMP-1 is not found involvement of a single collagenase were to emerge in in rodents, and yet cartilage and bone degradation any of the rheumatic diseases, then highly specific proceeds in rodent models of arthritis. MMP-13 also inhibitors could be tested in this disease. This might has a much wider substrate specificity and can effect further cleavage of collagen at the N-terminus of the avoid the side-effects seen previously and at least one metalloproteinase inhibitor in human arthritic synovium. ible for continually stimulating the immune system in
